Join
Live feed
·
PRReleasevia Quantisnow
Scholar Rock Holding Corporation logo

Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)

ByQuantisnow·Wall Street's wire, on your screen.
SRRK· Scholar Rock Holding Corporation
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SRRK (Scholar Rock Holding Corporation) and more on Quantisnow.